Healthcare Industry Insights

Tuesday, 25 February 2020

Biomarkers Market Size Worth $129.4 Billion By 2027

The global Biomarkers Market size is expected to reach over USD 129.4 billion by 2027, according to a new study conducted by Grand View Research Inc. It is anticipated to exhibiting a CAGR of 13.7%, during the forecast period. Factors, such as increasing collaborations and funds for R&D activities, rising consumer awareness, a widening patient base, and technological advancements collectively augmenting market growth.

The drug discovery segment contributed the highest revenue in 2019. Pharmaceutical companies focus on extensive R&D initiatives for the development of targeted therapeutics. Coordinated strategic efforts on biomarker development remain a searing trend among drug manufacturers, academic research institutions, commercial R&D organizations, nonprofitable health foundations, and federal government biomedical regulatory and research agencies.

North America continued to lead the biomarkers market in 2019, driven by an amplifying demand for personalized medicines, high disease prevalence, and proactive government initiatives. It is expected to maintain its lead over the forecast period. Asia Pacific is positioned to witness the fastest CAGR, over the forecast period, spearheaded by India.

Some key market players include Abbott; F. Hoffmann-La Roche Ltd.; Qiagen; Siemens Healthcare Private Limited; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Johnson & Johnson Services, Inc; Agilent Technologies, Inc.; and Epigenomics AG. The players are developing novel kits and therapies and drugs to target population in the areas with high unmet clinical needs.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/biomarkers-industry

Further key findings from the study suggest:

Safety biomarkers captured more than 41% market share in 2019, driven by increasing awareness regarding routine healthcare checkups and reduction in drug attrition
Validation biomarkers is expected to demonstrate the fastest CAGR through to 2027
Personalized medicine is likely to expand at a CAGR of 14.8% over the forecast period due to consumer awareness and preferences
Cancer dominated the disease segment in 2019, driven by a high disease burden and presence of a strong pipeline
Cardiovascular disease segment is projected to witness the fastest growth in the forthcoming years, supported by the growing obese population base and sedentary lifestyles

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Microscope Market Size is Estimated to Value $15.1 Billion By 2026

The global Microscope Market size is expected to reach USD 15.1 billion by 2026 registering a CAGR of 7.9%, according to a new study by Grand View Research, Inc. Growing demand for advanced and high resolution microscopes for conducting R&D in the fields, such as life sciences and nanotechnology, is expected to drive the market over the forecast period. Emergence of new application areas, such as quantum dots and miniature transistor chips, will further boost the market growth.

Quantum dots technology is currently in a nascent stage and is expected to cater to multiple application areas including in transistors, diode lasers, quantum computing, biological imaging, solid-state lighting, electroluminescent displays, and photo-voltaic cells. Optical devices led the market in 2018, owing to their large application base. However, due to high adoption of advanced microscopes, scanning probe and electron microscopes are expected to gain share over the coming years.

Scanning probe devices is expected to be the fastest-growing product segment from 2019 to 2026. Features, such as non-dependence on wavelength of the source light, resolving atoms, and generating better 3D maps of surfaces, are some of the factors expected to drive the demand of these products. North America led the global market, in terms of revenue, in 2018 and is likely to reach USD 4.7 billion by 2026.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/microscopes-industry

Further key findings from the study suggest:

Semiconductors and life sciences were the dominant application segments in the global microscope market
However, nanotechnology is expected to be the fastest-growing application with a CAGR of 9.3% from 2019 to 2026
Asia Pacific is expected to be the fastest-growing regional market with a CAGR of 9.1% from 2019 to 2026
High demand for semiconductors and positive outlook on application markets are expected to be the key drivers responsible for the market growth in the region
Key companies in the market include Olympus Corporation, Hitachi High-Technologies Corporation, Nikon Corporation, FEI Company, JEOL Ltd., Carl Zeiss, and Leica Microsystems

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Global Nurse Call System Market, 2020-2027 | 11.4 % CAGR Growth till 2027

The global Nurse Call Systems Market size is expected to reach USD 2.9 billion by 2027, expanding at a CAGR of 11.4%, according to a new report by Grand View Research, Inc. Increasing adoption of digital healthcare, growing demand for patient safety and care are expected to boost market growth. In addition, continuous technological advancements to bring new levels of communication enabling the widest range of applications configuration at home care, hospitals, or residential facilities are also expected to increase the demand for the market. In December 2018, Ascom Holdings AG has received the approval certificate from the U.S. Food and Drug Administration (FDA), as class II 510(k), for Digistat Smart Central software solution increasing the scope of the Ascom Healthcare to expand their presence in the U.S. hospitals.

With the increasing life expectancy and changing healthcare requirements, the burden on national insurance bodies has increased. Owing to this factor, Medicare penalizes healthcare facilities with hospital readmissions within 30 days. The government is providing funds for research, which can help caregivers to streamline the entire process with the aid of technology. For instance, in April 2015, the American Association of Critical-Care Nurses (AACN) granted USD 160,000 for appropriate and effective use of technology.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/nurse-call-system-equipments-industry

Further key findings from the report suggest:

The wired communication equipment segment dominated the market in 2019 due to ongoing advancements in technology and healthcare facilities. Rapid growth of wireless communication nurse call system can be attributed to factors such as low cost of installation, easy integration with other devices, and ease of mobility. In January 2019, the Hill Rom launched its LINQ mobile application for improvement in communication between the patient and caregiver formerly in U.S. and Canada with further expansion to Europe
In the type segment, nurse call integrated communication systems held the largest share of the nurse call system market in 2019, owing to the advancement in communication system, availability of data to be used by healthcare personnel, and rising demand for improved quality of care
Wanderer control dominated the application segment of the market in 2019 owing to ease of communication, growing demand for digital technology, and rising prevalence of aging population adopting nurse call systems
Hospitals have a major share of the end-use segment of the market in 2019, owing to the patient flow and the increasing chronic and emergency case patients. Hospitals are revamping their older nurse call systems and funding infrastructure supporting system integration. Moreover, researchers are filing patents for technologies that offer uninterrupted communication
North America was the largest regional market in 2019 owing to the establishment of separate certification and coding system and presence of key market players in the region. In October 2018, Tunstall Healthcare acquired Kanayo Software Inc., and EWII Telecare to expand its Connected Health solutions. The acquisition provided Tunstall with expertise in Software and App products in health and social care
Some key players in this market include Hill-Rom Holding, Inc., Tyco SimplexGrinnell, Ascom Holding, Honeywell International, Inc., Rauland-Borg Corporation, TekTone Sound & Signal Mfg., Inc., Stanley Healthcare, Azure Healthcare, West-Com Nurse Call Systems, Inc., and Critical Alert Systems LLC.

Injection Pen Market Size is Predicted to Witness 9.4% CAGR till 2025

The global Injection Pens/Injectable Pens/Pen Injectors Market is expected to reach USD 67.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 9.4% CAGR during the forecast period. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/injection-pens-market

Further key findings from the study suggest:

Rising incidence of diseases such as diabetes and arthritis is primarily boosting market growth
Increase in government healthcare expenditure and availability of favorable healthcare insurance policies in developed as well as developing countries is driving the market
By product, reusable injectable pens are the largest and fastest growing segment owing to the advantages associated with them such as cost effectiveness and patient convenience. Commercially available reusable injectable pens mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar, Bydureon, Epipen and Genotropin
By dosage, variable dosage is the fastest growing segment. Some of the customizable variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL Group, and Evo pen by Copernicus
North America dominates the market, followed by Europe. Technological advancements and increase in incidence of osteoporosis, arthritis, and anaphylaxis are factors that can be attributable to its largest market share
Asia Pacific is expected to be the fastest growing region over the forecast period. Better accessibility to healthcare, coupled with constantly increasing healthcare expenditure in the region, is fueling market growth
China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players. This is owing to favorable factors such as availability of labor and raw materials at significantly lower prices as compared to other regions
Key players in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz Inc.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Colposcopy Market 2018-2025 with Key Players | Karl Kaps GmbH & Co. KG; Carl Zeiss; Cooper Surgical, Inc. and Others

The global Colposcopy Market size is projected to reach USD 293.6 million by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 7.0% during the forecast period. Increasing investments in the medical imaging industry and rising cervical cancer screening in developing countries are poised to trigger the growth of the market. Developing countries offer new investment avenues to global market giants. Developing healthcare infrastructure and expanding patient pool are rendering emerging countries promising destinations for global players in the market.

As per the findings of the World Health Organization, the number of new cervical cancer cases are estimated to reach 570,000 by end of 2018, accounting for 6.6% of total cancers related only to females. The number of deaths registered due to this type of cancer is higher in developing countries. It can be reduced by implementing a program which provides early diagnosis and effective treatment.

Governments in emerging economies are focusing on augmenting reach of cancer screening programs, which in turn is anticipated to boost the adoption of colposcopes. In addition, major market players are adopting advanced technologies by integrating various digital platforms with colposcopy equipment. Advent of high resolution imaging devices is expected to follow up integration, which is likely to replace conventional colposcopes, hence influencing the growth of the market.

Mergers and acquisitions and service portfolio expansion are some of the key strategies adopted by major players. For instance, in September 2016, DYSIS introduced an advanced imaging technique that has the ability to detect neoplasia and precancerous cells, which will help in diagnosing cancer. Prominent market players are also focusing on increasing their geographical reach.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/colposcopy-market

Further key findings from the report suggest:

The video modality segment is projected to register the fastest growth during the forecast period
The pelvic segment is poised to exhibit a CAGR of over 7.1% during forecast period
The handheld segment is estimated to expand at a lucrative CAGR during the forecast period
Asia Pacific is anticipated to exhibit a CAGR of about 8.0% during the forecast period owing to improvised healthcare infrastructure, rising disposable income, and investments from global market players
Some of the key players in this market are Karl Kaps GmbH & Co. KG; Carl Zeiss; Cooper Surgical, Inc.; DYSIS Medical Ltd.; ATMOS Medizin Technik GmbH & Co. KG; OLYMPUS CORPORATION; McKesson Medical-Surgical Inc.; Ecleris S.R.L.; Optomic and Seiler Instrument Inc.

Embolic Protection Devices Market 2018-2026 with Key Players | Boston Scientific Corp.; Edward Lifesciences; Abbott Laboratories and Others

The global Embolic Protection Devices Market size is expected to reach USD 1.7 billion by 2026, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 8.4% during the forecast period. Rising incidences of cardiovascular and neurovascular diseases and growing adoption of minimally invasive diseases are propelling the market growth. Rising demand for technologically advanced embolic devices and increasing healthcare expenditure, resulting in huge funding and investments from multinational companies, are fueling the R&D in the global medical devices industry. This factor is also contributing toward the market growth.

On the other hand, the product failures and recalls may limit the market growth. Low reimbursement for stenting and presence of alternative treatment methods, such as the use of drugs, may also imped the market development. However, factors such as a rise in the number of Trans-catheter Aortic Valve Replacement (TAVR) procedures will support the market expansion. The number of TAVR centers in U.S. has increased from 156 in 2012 to 511 in 2017, and approximately 35,000 patients underwent TAVR in 2016 in U.S. alone. The distal occlusion systems segment is expected to register the highest CAGR over the forecast period.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/embolic-protection-devices-market

Further key findings from the study suggest:

Distal filter devices segment emerged as the largest segment owing to high demand for these devices
Neurovascular diseases accounted for the largest share in the application segment owing to the rising cases of neurological disorders
North America led the global embolic protection devices market with the largest share in 2017 and is likely to maintain this trend over the estimated period
Growing adoption of minimally invasive surgeries and increasing demand for novel technologies are facilitating the dominance of this region
The industry in the Asia Pacific is projected to witness swift growth during the forecast period owing to rapidly improving healthcare infrastructure and large target population base
Some of the key companies include Boston Scientific Corp.; Edward Lifesciences; Abbott Laboratories; Medtronic Plc; Cardinal Health, Inc.; Claret Medical, Inc.; and Innovative Cardiovascular Solutions, LLC

Metagenomics Market Size is Predicted to Witness 16.6% CAGR till 2025

The global Metagenomics Market size is expected to reach USD 1.40 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 16.6% during the forecast period. Rise in demand for microbial screening in food and chemical industries for commercial applications, coupled with rapid developments in bioinformatics and biotechnology tools, is anticipated to accelerate market growth in the coming years.

Key market participants are striving to capitalize potential avenues in the market by addressing challenges faced by research entities pertaining to data assembly, identification, and verification of rare metagenomes. Furthermore, companies operating in the molecular diagnostics and genomics arena are a playing crucial role in this market by partnering with metagenomics companies for development of novel tests for disease diagnosis.

For instance, in September 2017, IDbyDNA, Inc. and ARUP Laboratories co-developed Explify Respiratory-a metagenomic NGS test for screening of respiratory infections. The anticipated launch of many such novel tests is projected to boost the market during the forecast period.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/metagenomics-market

Further key findings from the report suggest:

Kits and reagents formed the largest segment by product in 2017 owing to frequent usage at various steps in microbial genomic studies
Surplus growth in genomics database with respect to types and numbers has led to rising demand for better data analysis solutions. As a result, the sequencing and data analytics services segment is expected to emerge as a lucrative source of revenue generation during the forecast period
Function driven technology held the major revenue share in 2017. Development of new screening procedures that facilitate rapid screening of large clone libraries has enabledfunctional detection of novel enzymes from metagenomes
Advancements in genetic tools have broadened the application scope of metagenomics to include targeting microbes responsible for inducing various cancer forms. This, in turn, is driving the application of metagenomic analysis in human health
North America dominated the market in 2017. Strong presence of key NGS leaders like Illumina and a substantial number of ongoing genomics-related studies in U.S. are major factors contributing to its large share
Some of the key competitors in the market are Illumina, Inc.; Promega Corporation; Novogene Corporation; Oxford Gene Technology, Inc.; Thermo Fisher Scientific, Inc.; TAKARA BIO INC.; Danaher; QIAGEN; and ELITechGroup
Acquisition of small players with a strong product portfolio is a prominently adopted strategy by dominant players. For instance, in August 2016, PerkinElmer acquired Bioo Scientific Corporation-provider of 16S & 18S library preparation kits for metagenome studies
Competitors are also involved in collaborations with bioinformatics companies for co-development of novel platforms for metagenomics analysis.